Hansa Biopharma AB (publ) (LON:0RC7)

Market Cap	136.92M
Revenue (ttm)	14.01M
Net Income (ttm)	-48.25M
Shares Out	n/a
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,100
Average Volume	3,186
Open	24.20
Previous Close	24.38
Day's Range	24.10 - 24.24
52-Week Range	20.10 - 57.30
Beta	1.53
RSI	56.94
Earnings Date	Jul 17, 2025

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 135
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RC7

Financial Performance

In 2024, Hansa Biopharma AB's revenue was 171.32 million, an increase of 27.76% compared to the previous year's 134.09 million. Losses were -807.24 million, -2.94% less than in 2023.

Financial numbers in SEK